CA2977812A1 - Uses of pthrp analogue in reducing fracture risk - Google Patents

Uses of pthrp analogue in reducing fracture risk Download PDF

Info

Publication number
CA2977812A1
CA2977812A1 CA2977812A CA2977812A CA2977812A1 CA 2977812 A1 CA2977812 A1 CA 2977812A1 CA 2977812 A CA2977812 A CA 2977812A CA 2977812 A CA2977812 A CA 2977812A CA 2977812 A1 CA2977812 A1 CA 2977812A1
Authority
CA
Canada
Prior art keywords
abaloparatide
bmd
bone
teriparatide
treated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2977812A
Other languages
English (en)
French (fr)
Inventor
Gary Hattersley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Radius Health Inc
Original Assignee
Radius Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56849024&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2977812(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Radius Health Inc filed Critical Radius Health Inc
Publication of CA2977812A1 publication Critical patent/CA2977812A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2977812A 2015-03-03 2016-03-03 Uses of pthrp analogue in reducing fracture risk Pending CA2977812A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201562127729P 2015-03-03 2015-03-03
US62/127,729 2015-03-03
US201562165841P 2015-05-22 2015-05-22
US62/165,841 2015-05-22
US201562201564P 2015-08-05 2015-08-05
US62/201,564 2015-08-05
US201562239733P 2015-10-09 2015-10-09
US62/239,733 2015-10-09
US201662278762P 2016-01-14 2016-01-14
US62/278,762 2016-01-14
PCT/US2016/020787 WO2016141250A1 (en) 2015-03-03 2016-03-03 USES OF PTHrP ANALOGUE IN REDUCING FRACTURE RISK

Publications (1)

Publication Number Publication Date
CA2977812A1 true CA2977812A1 (en) 2016-09-09

Family

ID=56849024

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2977812A Pending CA2977812A1 (en) 2015-03-03 2016-03-03 Uses of pthrp analogue in reducing fracture risk

Country Status (8)

Country Link
US (9) US20170065682A1 (https=)
EP (2) EP3265115B1 (https=)
JP (5) JP6755256B2 (https=)
AU (3) AU2016226103A1 (https=)
CA (1) CA2977812A1 (https=)
DK (1) DK3265115T3 (https=)
ES (1) ES2927067T3 (https=)
WO (1) WO2016141250A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10568937B2 (en) 2016-04-18 2020-02-25 Radius Health, Inc. Formulations of abaloparatide, transdermal patches thereof, and uses thereof
CA3045458A1 (en) * 2016-11-30 2018-06-07 Purdue Research Foundation Fracture targeted bone regeneration through parathyroid hormone receptor stimulation
WO2019232283A1 (en) 2018-05-30 2019-12-05 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
IL284533B2 (en) * 2019-01-11 2024-02-01 Radius Health Inc Methods for detecting antibodies to neutralizing thyroid hormone (PTH) and thyroid hormone-related peptide (PTHRP) analog
JP7454511B2 (ja) 2019-02-14 2024-03-22 富士フイルム株式会社 骨折リスク評価値取得装置及びその作動方法並びに骨折リスク評価値取得プログラム
EP4027899A4 (en) * 2019-09-12 2023-08-16 Radius Health, Inc. METHODS OF ENHANCING SPINE FUSION USING ABALOPARATIDE
CN112646042A (zh) * 2019-10-10 2021-04-13 陕西麦科奥特科技有限公司 活性多肽化合物
WO2022149066A1 (en) * 2021-01-05 2022-07-14 Radius Health, Inc. Treatment of long bone fractures with abaloparatide
US20220378881A1 (en) * 2021-05-25 2022-12-01 Radius Health, Inc. Treatment and prevention of osteoporosis in high body mass index individuals
WO2025032376A1 (en) * 2023-08-04 2025-02-13 Precise Biopharma Pvt Ltd A room temperature stable solution for injection of abaloparatide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
EP1531855A4 (en) * 2002-01-10 2009-07-22 Osteotrophin Llc TREATMENT OF BONE DISEASES WITH SKELETTAL ANABOLIKA
AU2006343306A1 (en) * 2005-09-06 2007-11-15 Zelos Therapeutics, Inc. Parathyroid hormone analogues and methods of use
HRP20120643T1 (hr) * 2006-08-25 2012-08-31 Ares Trading S.A. Liječenje poremećaja hrskavice sa fgf-18
BRPI0719821B8 (pt) * 2006-10-03 2021-05-25 Ipsen Pharma Sas composição estável na armazenagem apropriada para administração a pacientes
US7803770B2 (en) * 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
WO2010022176A1 (en) * 2008-08-19 2010-02-25 Ferring International Center S.A. Methods of treatment for skeletal conditons
EP2699252B1 (en) * 2011-04-22 2017-10-25 Radius Health, Inc. Method of drug delivery for pth, pthrp and related peptides
CN104619727B (zh) * 2012-06-25 2019-04-05 布里格姆及妇女医院股份有限公司 靶向治疗
KR20180067573A (ko) * 2015-10-09 2018-06-20 라디우스 헬쓰, 인코포레이티드 PTHrP 유사체의 제형, 이의 경피 패취, 및 이의 용도

Also Published As

Publication number Publication date
EP4137147A2 (en) 2023-02-22
EP3265115A4 (en) 2019-05-22
EP4137147A3 (en) 2023-04-05
US20170065682A1 (en) 2017-03-09
JP2020189884A (ja) 2020-11-26
EP3265115A1 (en) 2018-01-10
WO2016141250A1 (en) 2016-09-09
JP2018508530A (ja) 2018-03-29
US20230381283A1 (en) 2023-11-30
AU2024202952A1 (en) 2024-05-23
AU2016226103A1 (en) 2017-08-31
JP2025100689A (ja) 2025-07-03
US20200061160A1 (en) 2020-02-27
US20200376088A1 (en) 2020-12-03
ES2927067T3 (es) 2022-11-02
US20220125887A1 (en) 2022-04-28
JP7049412B2 (ja) 2022-04-06
JP2022075999A (ja) 2022-05-18
US20230321199A1 (en) 2023-10-12
US20250195619A1 (en) 2025-06-19
JP2023129523A (ja) 2023-09-14
EP3265115B1 (en) 2022-06-22
US20170368148A1 (en) 2017-12-28
JP6755256B2 (ja) 2020-09-16
AU2020267182A1 (en) 2020-12-03
US20250387454A1 (en) 2025-12-25
DK3265115T3 (da) 2022-09-05

Similar Documents

Publication Publication Date Title
US20250195619A1 (en) Uses of pthrp analogue in reducing fracture risk
JP6177718B2 (ja) 骨の靭性、及び、剛性を増し、骨折を減少させる方法
Tay et al. Discontinuing denosumab: can it be done safely? A review of the literature
Chew et al. Abaloparatide: recombinant human PTHrP (1–34) anabolic therapy for osteoporosis
Gabet et al. Intermittently administered parathyroid hormone 1–34 reverses bone loss and structural impairment in orchiectomized adult rats
Kim et al. Early and multiple doses of zoledronate mitigates rebound bone loss following withdrawal of receptor activator of nuclear factor kappa-B ligand inhibition
CA2383574A1 (en) Method for reducing the risk of cancer
HK40088026A (en) Uses of abaloparatide in reducing fracture risk
US20220378881A1 (en) Treatment and prevention of osteoporosis in high body mass index individuals
Devogelaer et al. Biologicals in osteoporosis: teriparatide and parathyroid hormone in women and men
Cosman Teriparatide and abaloparatide treatment for osteoporosis
Tabacco et al. PTH and PTHrP analogs: Treatment of osteoporosis
ADAMI et al. Parathyroid hormone and
Mass et al. Current Issues in Osteoporosis Therapy

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210302

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250226

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250226

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250226

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250408

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250806

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250807

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250915

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250915